What is Genmab AS's share price today?
Genmab AS (GMAB) share price today is $54.81 as of November 5, 2026 at 2:22 AM IST. The stock touched a day high of $55.98 and a day low of $53.76.What exchange does Genmab AS stock trade on, and under what ticker symbol?
Genmab AS stock trades on NASDAQ under the ticker symbol GMAB.What is Genmab AS's market capitalization?
Genmab AS's market capitalization is $33.77B as of November 5, 2026 at 2:22 AM IST.What is Genmab AS's price-to-earnings (P/E) ratio?
Genmab AS's price-to-earnings (P/E) ratio is 43.24 as of November 4, 2026.What is Genmab AS's price-to-book (P/B) ratio?
Genmab AS's price-to-book (P/B) ratio is 5.88 as of November 4, 2026.Can Indian investors buy Genmab AS shares?
Yes, You can buy Genmab AS shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Genmab AS shares from India?
Indian investors can buy Genmab AS shares in three steps: 1. Search Genmab AS on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Genmab AS shares for Indian investors?
Since Genmab AS trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Genmab AS shares via Tickertape?
Indian investors can start investing in Genmab AS (GMAB) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.1824 shares at the current price of $54.81.
Key Metrics
Key Metrics
Close price divided by the earnings per share for the trailing twelve months
Close price divided by the book value per share at the end of the most recent quarter
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
Net profit divided by the total revenue for the most recent financial year
Annual dividend per share for the trailing twelve months divided by the close price
Based on 12 analysts reports
Price Upside
+17%
Earnings Growth
-31.58%
Rev. Growth
+709.65%
Company Profile
Company Profile
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
All values in $
All values in $
Revenue Forecast
Revenue Forecast
The next fiscal year's mean estimate implies 709.65% growth, versus a trailing 3-year CAGR of -36.45%.
All values in $ Billion
All values in $ Billion
Earnings Per Share Forecast
Earnings Per Share Forecast
The next fiscal year's mean estimate implies -31.58% growth, versus a trailing 3-year CAGR of 13.81%.
All values in $
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
| Financial Year | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.60 | 0.77 | 5.54 | 6.44 | 0.10 | 0.92 | 1.02 | 1.05 | 0.89 | 1.15 |
| Gross Profit | 0.57 | 0.75 | 5.26 | 6.10 | 0.09 | 0.86 | 0.96 | 0.97 | 0.83 | 1.07 |
| Net Income | 0.19 | 0.20 | 1.26 | 3.84 | 0.02 | 0.33 | 0.40 | 0.03 | 0.05 | 0.30 |
| Net Profit Margin | 31.84% | 26.05% | 22.85% | 59.69% | 27.27% | 36.32% | 39.23% | 2.93% | 5.91% | 26.23% |
Peers
Peers & Comparison
Peers & Comparison
HealthcareBiotechnology
Valuation
Returns
Forecast
| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Genmab AS | 43.24 | 5.88 | 8.56 |
| AbbVie Inc | 50.67 | 50.45 | 0.60 |
| Amgen Inc | 28.90 | 21.55 | 2.77 |
The 12-month consensus target implies 17.00% growth, versus a trailing 3-year CAGR of 24.04%.